A team led by Guosong Hong at Stanford has figured out how to switch on a light source deep inside a living animal without ever cutting into it. Their tool: focused ultrasound beams aimed at tiny engineered particles flowing through the bloodstream. When the ultrasound hits those particles, they glow, producing enough light to activate genetically modified neurons buried beneath the skin.
The results, published in Nature Materials in early 2026, represent a significant step for optogenetics, the technique of controlling cells with light. For more than a decade, optogenetics has been one of neuroscience’s most powerful tools, but it has been held back by a stubborn physical reality: visible light scatters and dies out within a few millimeters of entering biological tissue. Reaching deep brain structures or internal organs has required surgically implanted fiber optics or tiny LEDs, bringing risks of infection, tissue damage, and limited reach.
The Stanford approach sidesteps that barrier entirely. Ultrasound, unlike light, passes through tissue with minimal scattering. By engineering nanoparticles that convert mechanical ultrasound energy into photons, Hong’s group created what is effectively a steerable internal lamp, activated and aimed from outside the body.
How the system works
The core technology relies on what the researchers call mechanoluminescent nanotransducers, or MLNTs. These nanoscale particles are injected intravenously and circulate through the bloodstream. When a focused ultrasound beam converges on a specific tissue region, the mechanical pressure triggers the MLNTs in that area to emit light. Because the ultrasound beam can be scanned and modulated, the researchers can direct illumination to precise locations without any implanted hardware.
In mouse experiments, the team demonstrated that MLNT-generated light was bright enough to drive optogenetic responses in targeted neurons. The ultrasound beam could be repositioned to illuminate different tissue regions during a single session, a capability the authors describe as spatial programmability.
A detailed methods paper in Nature Protocols, published in 2023, lays out foundational procedures that preceded the 2026 Nature Materials results: how to synthesize and characterize the nanotransducers, calibrate the ultrasound hardware, run tissue-phantom tests, and perform in vivo behavioral and histological assays. The protocols paper established the methodological groundwork, while the later Nature Materials study reported the primary in vivo optogenetic findings. An open-access version on PubMed Central includes raw behavioral data, analysis scripts, and explicit discussion of limitations. That level of methodological transparency is uncommon for a technology this early in development and gives other labs a genuine blueprint for replication.
Why it matters for optogenetics
The light-delivery problem in optogenetics is not new, and neither are attempts to solve it. Other groups have explored upconversion nanoparticles that absorb near-infrared light and re-emit visible wavelengths, as well as wireless micro-LED implants small enough to be injected. Sonoluminescence, where collapsing bubbles in liquid produce brief flashes, and chemiluminescent systems triggered by ultrasound have also been investigated.
What distinguishes the Stanford platform is its combination of features: the particles circulate in the bloodstream rather than requiring surgical placement, the ultrasound beam can be steered in real time, and the emitted light is tuned to wavelengths that match common optogenetic actuators. Some competing ultrasound-to-light systems have been optimized for imaging rather than delivering the sustained photon doses needed to activate light-sensitive proteins in cells. That difference in design priority is critical when evaluating which platforms might eventually work for therapy or chronic neuroscience experiments.
No head-to-head comparisons between these approaches have been published, so ranking them on metrics like penetration depth, spatial resolution, or total light output remains difficult. But the Stanford work is among the first to demonstrate functional optogenetic activation at depth using a fully non-invasive, bloodstream-based delivery system in a living animal.
What has not been answered yet
The gap between a successful mouse experiment and anything resembling a human therapy is wide, and the researchers are transparent about what they do not yet know.
No human trials or preclinical regulatory filings have been announced. The ultrasound power levels, duty cycles, and focusing parameters validated in a mouse brain may not translate directly to a human cortex or deep organ, where tissue volumes and blood flow dynamics are fundamentally different. Scaling the technology will require new engineering work that the current papers do not address.
Long-term safety data are also missing. The published experiments describe acute tolerability and short-term histological assessments, but there is no multi-month tracking of how the body clears the particles, whether they accumulate in the liver or spleen, or whether repeated dosing triggers immune responses or cumulative toxicity.
The nanotransducers themselves have a limited functional window. Their brightness decays over time in the bloodstream, and the papers acknowledge that this window may not yet be long enough for realistic therapeutic sessions or extended behavioral studies. Improving particle stability and optimizing dosing schedules are active areas of work.
There is also a subtle experimental confound. Focused ultrasound at certain frequencies can stimulate auditory neural circuits in animals, even when aimed at non-auditory brain regions. The Stanford team flags this in their limitations sections and uses control conditions to address it, but fully disentangling optogenetic responses from ultrasound-induced auditory artifacts will require further experiments, potentially including tests in animals lacking functional hearing or light-sensitive channels.
On the commercial side, the picture is blank. The published papers list academic and grant funding but disclose no patents, industry partnerships, startup activity, or regulatory interactions. Manufacturing MLNTs at clinical grade, with tight control over particle size, composition, and surface chemistry, could be expensive and technically demanding. The focused-ultrasound hardware needed to activate them, especially if it must integrate with MRI systems or operate at a patient’s bedside, adds another layer of cost and complexity.
Signals that would strengthen the case for clinical translation
For anyone following non-invasive brain technologies or the future of optogenetics, the Stanford work sits at an interesting inflection point. It has cleared the animal-experiment stage with peer-reviewed validation and unusually detailed methodological disclosure, putting it ahead of many competing concepts that remain theoretical or limited to bench-top demonstrations.
But the historical record of translational neuroscience is sobering. The distance between a mouse proof of concept and an approved human therapy is typically measured in years, substantial funding, and multiple rounds of safety and efficacy testing. The most informative near-term signals will be independent replication by other laboratories, longer-duration animal studies probing chronic safety, and early engineering efforts to adapt the system for larger brains and organs.
If those milestones arrive, and if the nanotransducers can be manufactured reliably at scale with tunable light output for different optogenetic tools, the technology could eventually offer neuroscientists and clinicians something that has never existed: a way to precisely control cells with light, anywhere in the body, without a single incision.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
